This review by Graves et al. synthesizes emerging evidence that senescent brain cells are heterogeneous, dynamic, and context dependent, highlighting determinants of diverse programs and emphasizing integration of single-cell-and spatial-omics with mouse studies to facilitate mechanistic insights and possible therapeutics.
At Lifespan, our mission is to help you and your loved ones live your longest, healthiest lives while supporting medical research into breakthroughs to improve all lives.
We’re building the world’s largest longevity community: Join us at https://lifespan.com.
Follow us on YouTube, Apple, and Spotify for new Lifespan episodes every 2 weeks.
In this episode of Lifespan, Dr. David Sinclair, A.O., Ph.D. – Professor of Genetics at Harvard Medical School and pioneer in longevity research – explores the science of eye aging, vision loss, and emerging strategies to preserve vision throughout life.
Dr. Sinclair shares an inside update on ER-100, including his team’s successful restoration of vision in non-human primates and the launch of the world’s first FDA-cleared age reversal human clinical trial. This Phase 1 clinical trial will evaluate the safety of epigenetic cellular restoration as a therapy.
Additionally, drawing on decades of research, Dr. Sinclair explains why the eyes may offer one of the earliest windows into biological aging, how everyday factors such as sleep position, alcohol consumption, and intraocular pressure influence long-term eye health, and what the latest evidence reveals about nutrition, supplements, and the connection between the eyes and the brain.
The next 10 years may add decades to human lifespan by compressing the time it takes to understand, treat, and prevent disease. In this episode, Dr. Derya Unutmaz explains why accelerating AI could transform drug discovery, shorten clinical trials, and push cancer treatment toward increasingly personalized interventions. He also reframes AI not as an existential threat, but as a medical enabler that doctors may soon be ethically obligated to use.
Get weekly, protocol-driven research breakdowns from Dr. Rhonda Patrick to advance healthspan, longevity, brain health, and resilience: https://www.foundmyfitness.com/newsle… 00:00:00 Introduction 00:02:16 Why the next 10 years may add 50 to your lifespan 00:06:25 How AI is transforming drug discovery 00:11:55 Could digital twins shorten clinical trials? 00:14:31 Can AI predict drug safety and efficacy? 00:18:46 Have we already reached AGI? 00:24:28 Why AI may be medicine’s greatest force multiplier 00:30:41 Can AI replicate a scientist’s biological intuition? 00:37:22 Is it malpractice for doctors not to use AI? 00:43:24 What happens when AI monitors disease in real time? 00:46:58 Which AI models should doctors trust? 00:52:34 Claude vs. GPT—does the model matter for diagnosis? 00:56:04 Generalist vs. specialized AI—which works better in medicine? 00:59:30 Why cancer is so hard to cure 01:03:24 Could cancer be curable within a decade? 01:07:35 Can AI design cancer treatments on demand? 01:09:37 How AI could curb overtreatment and side effects 01:12:33 Predicting cancer years before it forms—is it possible? 01:18:55 Why biology could go exponential with AI 01:24:04 Why aging may be easier to prevent than reverse 01:29:56 Can the body be engineered to resist aging? 01:35:13 Can AI model how gene therapy will behave? 01:39:17 What people who reach 110+ reveal about Human 2.0 01:41:27 From Dolly to Yamanaka factors—the case for cellular age reversal 01:46:02 Why full-body rejuvenation is an engineering problem 01:53:49 What happens when AI reasons longer about biology? 01:56:31 The biosecurity dilemma of powerful AI 02:01:17 What should we actually measure to track aging? 02:07:40 How old immune cells distort aging clocks 02:10:28 Why reversing brain aging is uniquely difficult 02:16:55 The ultimate prompt for extending lifespan 02:18:56 What data does a true digital twin need? 02:23:38 How to build a mini digital twin today 02:28:32 How to give AI a long-term memory of your data 02:31:39 Why personal baselines matter for AI advice Derya Unutmaz, M.D. X: https://twitter.com/DeryaTR_ EPISODE LINKS Show notes & transcript: https://www.foundmyfitness.com/episod… PODCAST INFO Apple Podcasts: https://podcasts.apple.com/us/podcast… Spotify: https://open.spotify.com/episode/4BPh… SUPPORT MY MISSION Access more than 130 episodes of my premium podcast (The Aliquot) when you become a FoundMyFitness Premium Member: https://www.foundmyfitness.com/crowds… #ai.
CHAPTERS:
00:00:00 Introduction.
00:02:16 Why the next 10 years may add 50 to your lifespan.
00:06:25 How AI is transforming drug discovery.
00:11:55 Could digital twins shorten clinical trials?
00:14:31 Can AI predict drug safety and efficacy?
00:18:46 Have we already reached AGI?
00:24:28 Why AI may be medicine’s greatest force multiplier.
00:30:41 Can AI replicate a scientist’s biological intuition?
00:37:22 Is it malpractice for doctors not to use AI?
00:43:24 What happens when AI monitors disease in real time?
00:46:58 Which AI models should doctors trust?
00:52:34 Claude vs. GPT—does the model matter for diagnosis?
00:56:04 Generalist vs. specialized AI—which works better in medicine?
00:59:30 Why cancer is so hard to cure.
01:03:24 Could cancer be curable within a decade?
01:07:35 Can AI design cancer treatments on demand?
01:09:37 How AI could curb overtreatment and side effects.
01:12:33 Predicting cancer years before it forms—is it possible?
01:18:55 Why biology could go exponential with AI
01:24:04 Why aging may be easier to prevent than reverse.
01:29:56 Can the body be engineered to resist aging?
01:35:13 Can AI model how gene therapy will behave?
01:39:17 What people who reach 110+ reveal about Human 2.0
01:41:27 From Dolly to Yamanaka factors—the case for cellular age reversal.
01:46:02 Why full-body rejuvenation is an engineering problem.
01:53:49 What happens when AI reasons longer about biology?
01:56:31 The biosecurity dilemma of powerful AI
02:01:17 What should we actually measure to track aging?
02:07:40 How old immune cells distort aging clocks.
02:10:28 Why reversing brain aging is uniquely difficult.
02:16:55 The ultimate prompt for extending lifespan.
02:18:56 What data does a true digital twin need?
02:23:38 How to build a mini digital twin today.
02:28:32 How to give AI a long-term memory of your data.
02:31:39 Why personal baselines matter for AI advice.
Derya Unutmaz, M.D.
X: https://twitter.com/DeryaTR_
EPISODE LINKS
Show notes & transcript: https://www.foundmyfitness.com/episod…
💬 Artificial intelligence and big data are flooding discovery pipelines with high-potential drug candidates, but this rapid innovation has created a new challenge. Simply put, our capability to design miracle molecules is vastly outstripping our technology to mass-manufacture them safely for the global public. Moving drug making from the scale of lab flasks to commercial bioreactors introduces non-linear biological and engineering shifts that can undermine tasks like purification.
⚡In this New Scientist CoLab podcast, experts from global life sciences leader Cytiva explain the hidden, high-stakes science of purification that is required to close the gap between drug discovery and the pharmacy shelf.
Take a blood sample from someone in the dead of winter. Take another in midsummer. Same person, same laboratory. And yet, at the level of gene activity, the molecular picture can look surprisingly different. This is not an anomaly. This, a new Nature Communications study argues, is simply how human biology works, and it has significant implications for the way biomarkers have traditionally been studied.
Researchers from Kiel University’s Excellence Cluster PMI, KU Leuven and the German Center for Neurodegenerative Diseases (DZNE) in Bonn tracked 333 volunteers in Flanders over six months, drawing blood three times and measuring the activity of roughly 14,000 genes on each occasion.
What they found suggests that an important source of biological variation has been underappreciated in many clinical studies: in 85% of all genes, the variation within a single person over time is larger than the variation between different people. In other words, for most genes, the largest differences are observed between two time points in the same individual rather than between different individuals.
Fusion at high temperatures powers the sun and, if harnessed, could provide a potential source of energy here on Earth. But controlling fusion reactions has other benefits. The process also generates subatomic particles called neutrons that are used in a range of applications spanning medicine, research and national security.
Scientists at the University of California, Davis, and the Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab) have found that the materials surrounding a fusion reaction can dramatically increase how often it occurs, particularly at low energies where fusion is rare. Their study is published in Nature Communications. The study’s first author is Micah Karahadian, a doctoral candidate in Munday’s lab at UC Davis.
Their approach establishes a way to study and engineer nuclear reactions within solid materials, opening a new field of “materials-driven fusion.” Instead of designing materials just to survive the harsh conditions of fusion, researchers might be able to design materials that boost the reaction under specific conditions, similar to the way catalysts speed up chemical processes.
Crop production faces threats from plant pathogens. Traditional disease-resistance breeding relies heavily on natural plant resistance genes that encode immune receptors adapted to particular pathogens. However, rapidly evolving pathogens frequently overcome these natural defenses, and the limited diversity of naturally occurring immune receptors makes it difficult to develop crops with durable resistance.
Now, a team led by Professor Gao Caixia at the Institute of Genetics and Developmental Biology (IGDB) of the Chinese Academy of Sciences has developed a programmable platform for the on-demand design of synthetic plant immune receptors (SPIRs) that recognize proteins from diverse plant pathogens.
The study was published online in Science on July 23.
